ArticleBMJ global health2024
Disparities in availability of new cancer drugs worldwide: 1990-2022.
Article in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Natural flavonoid isoorientin and its anticancer mechanisms: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Pricing of innovative medicines and advanced therapies worldwide: an scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Global disparities in regulatory approval of prophylactic vaccines, 2005-2024.Journal of global health · 2026Article
- Drug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics.Health affairs scholar · 2026Article
- Accessibility of Biologic Drugs in Morocco: Comparison with FDA and EMA Approvals (2015-2025).Journal of market access & health policy · 2026Article
- Breast Cancer Patient Attitudes Towards Oncology Drug Costs in Ireland.Current oncology (Toronto, Ont.) · 2026Article
- A study on the availability of national centralized drug procurement in regions with different levels of economic development: an investigation and analysis of 31 provincial-level administrative regions in China.Frontiers in pharmacology · 2026Article
- From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies.European journal of drug metabolism and pharmacokinetics · 2026Review
- Glycogen-Rich Clear Cell Carcinoma of the Breast: Report of Two New Cases and an Updated Literature Review.Acta medica academica · 2025Review
- Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment.Future oncology (London, England) · 2025Article
- Extent and causes of the collapse in the registration of innovative medications in Lebanon: A mixed-methods analysis.PloS one · 2025Article
- Anticancer Drug Approval in China: From Acceleration of Access to Certainty of Benefits.Health data science · 2025Article
- Head and neck cancer - emerging targeted therapies.Frontiers in oncology · 2025Review
- Evaluation of In Vitro Biological Activity of Flavanone/Chromanone Derivatives: Molecular Analysis of Anticancer Mechanisms in Colorectal Cancer.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite progress in the development of new cancer drugs, concerns about equity of access remain. This study aimed to examine the availability and timeliness of availability of new cancer drugs around the globe over the past three decades and their associations with country characteristics.
methodsFrom a pharmaceutical intelligence database we identified new cancer drugs launched between 1990 and 2022. We calculated the number of new drugs launched in each country and the delay in launches. Using a multivariable linear regression and a Cox regression model with shared frailty, we examined the associations of the country's Gross National Income (GNI) per capita, cancer incidence, number of physicians per population, and Gini index with the number of new cancer drug launches and launch delay in a country, respectively.
resultsA total of 568 cancer drugs were launched for the first time globally between 1990 and 2022. Among these, 35% had been launched in only one country by 2022, 22% in 2-5 countries, 15% in 6-10 countries, and 28% in more than 10 countries. The number of new cancer drugs launched in a country in this period ranged from 0 to 345. The average delays from the first global launch to the second, third, fourth, and fifth launch were 18.0 months, 24.3 months, 32.5 months, and 39.4 months, respectively. Our multivariate models showed that higher GNI per capita and cancer incidence in a country were associated with more launches and shorter delays.
conclusionThis research reveals significant disparities in the availability and timeliness of availability of new cancer drugs across countries. These disparities are likely to have contributed to the poor cancer outcomes observed in many countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.